[Pharmacokinetics of a new antidiabetic agent in patients with limited kidney function].
D005243:Feces / Q000032:analysis; D005260:Female; D006207:Half-Life; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000139:chemically induced / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010615:Phenacetin / Q000009:adverse effects; D013453:Sulfonylurea Compounds / Q000032:analysis / Q000097:blood / Q000378:metabolism / Q000494:pharmacology* / Q000652:urine; D014316:Tritium
D013453:Sulfonylurea Compounds; D014316:Tritium; D010615:Phenacetin
Pharmakokinetik eines neuen Antidiabetikums bei Patienten mit eingeschränkter Nierenfunktion.